Outlook Therapeutics, INC Schedule 13G passive stakes

Intracoastal Capital LLC and its principals have reported a 4.99% beneficial ownership stake in Outlook Therapeutics following a recent securities purchase agreement.

Sphera Funds Management Ltd. and its affiliates reported a 4.69% beneficial ownership stake in Outlook Therapeutics, Inc., primarily through exercisable warrants.

Empery Asset Management, along with Ryan M. Lane and Martin D. Hoe, reported a 4.99% beneficial ownership stake in Outlook Therapeutics, Inc., primarily through warrants.

Tang Capital Management and affiliates report a 3.4% passive stake in Outlook Therapeutics, Inc., holding 1.5 million shares issuable upon warrant exercise.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, filed an amendment to their Schedule 13G, disclosing a continued beneficial ownership of 4.99% in Outlook Therapeutics, Inc.

Empery Asset Management, LP, along with its managing members Ryan M. Lane and Martin D. Hoe, reported a 7.57% beneficial ownership stake in Outlook Therapeutics, Inc. common stock.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly filed an amended Schedule 13G, disclosing a shared beneficial ownership of 6.37% in Outlook Therapeutics, Inc., totaling 2,220,000 shares.

Tang Capital Management and affiliated entities have filed an amended Schedule 13G, reporting a combined beneficial ownership of 5.6% in Outlook Therapeutics, Inc., primarily through common stock and exercisable warrants.

Sphera Funds Management Ltd. and its affiliated entities have disclosed a 7.49% beneficial ownership stake in Outlook Therapeutics, Inc., comprising common stock and exercisable warrants.

Sphera Funds Management Ltd. and its affiliates have disclosed a beneficial ownership stake of 5.21% in Outlook Therapeutics, Inc., totaling 1,714,284 shares, including exercisable warrants.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, have jointly disclosed a beneficial ownership of 8.18% in Outlook Therapeutics, Inc., totaling 2,220,000 shares.

Tang Capital Management, Kevin Tang, and affiliated entities have reported a combined beneficial ownership of 6.4% in Outlook Therapeutics, Inc., totaling 1,682,502 shares.